$1.75
+0.13 (+8.02%)
Open$1.63
Previous Close$1.62
Day High$1.82
Day Low$1.63
52W High$38.77
52W Low$17.44
Volume—
Avg Volume603.1K
Market Cap67.31M
P/E Ratio26.65
EPS$1.06
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+1,617.1% upside
Current
$1.75
$1.75
Target
$30.05
$30.05
$22.12
$30.05 avg
$38.96
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 11.43M | 10.74M | 10.31M |
| Net Income | -2,402,162 | -1,945,366 | -2,138,218 |
| Profit Margin | -21.0% | -18.1% | -20.7% |
| EBITDA | -3,961,862 | -3,629,854 | -3,514,676 |
| Free Cash Flow | -2,281,552 | -2,429,555 | -1,597,015 |
| Rev Growth | +22.4% | -6.0% | +21.1% |
| Debt/Equity | 1.10 | 1.30 | 1.15 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |